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Summary Thirty-one cervical biopsies of invasive carcinoma have been studied by immunohistochemical
means using the monoclonal antibody Ki67 to determine tumour cell proliferation rates. A wide range (10-
50%) in the extent of Ki67 staining (expressed as the percentage of labelled tumour cells) was observed
indicating considerable variation on tumour growth rates. There was no significant relationship between the
percentage of positive cells and conventional histological parameters such as cell type or tumour
differentiation. Immunostaining with monoclonal antibody Ki67 therefore provides a new approach to the
assessment of cervical tumour biopsies which will require long term clinical follow-up to establish its
prognostic significance.
Carcinoma of the cervix is currently the subject of
considerable attention since it is hoped that extensive
screening programmes coupled with effective early treatment
will prevent later invasive disease. Nevertheless the
prevalence of invasive cervical cancer remains high and there
is evidence that its incidence is rising, particularly amongst
younger sexually active women (MacGregor, 1982).
The clinical behaviour of invasive carcinoma of the cervix
is not uniform but covers a wide spectrum from cases that
are relatively indolent to those having a rapidly progressive
course (Richart & Barton, 1969). A reliable marker of
prognosis in individual cases would therefore be very useful.
As yet the value of histological and immunocytochemical
assessments for predicting the clinical course of cervical
cancer remains controversial. Studies of cell size, tumour
differentiation or presence of antigenic markers each
have their advocates (Ng & Atkin, 1973; van Nagell et al.,
1977; Bobrow et al., 1986) and opponents (Crissman et al.,
1985; Goellner, 1976; Wells et al., 1986; Fray et al., 1984).
Measurement of the tumour growth fraction in cervical
carcinoma appears to offer a potentially valuable approach
to this problem but has not been widely introduced due to
the time consuming and technically difficult nature of
methods involving the incorporation of DNA precursors
tritiated thymidine or bromodeoxyuridine into tumour cells.
Recently a monoclonal antibody Ki67 has been developed
which identifies a nuclear antigen in human cells at all stages
of the cell cycle except Go (Gerdes et al., 1984a). The
chemical nature of the antigen recognized by Ki67 has not
yet been determined and its functional role is unclear.
However a good correlation has been shown between the
immunocytochemical labelling of cell nuclei with Ki67 and
other methods of assessing cell proliferation, e.g. flow
cytometry and autoradiography (Gerdes et al., 1984a).
Preliminary studies of lymphoma (Gerdes et al., 1984b; Hall
et al., 1987), breast cancer (Gerdes et al., 1986; Barnard et
al., 1987) and carcinoma of the lung (Gatter et al., 1986)
have shown that monoclonal antibody Ki67 gives a rapid
and reliable estimate of the tumour growth fraction.
In the present study 31 cases of invasive carcinoma of the
cervix (both adenocarcinoma and squamous carcinoma) were
immunostained with Ki67 and the percentage of labelled
nuclei counted. The aims of this study were to establish
whether biopsies of cervical carcinoma provided suitable
material to study using Ki67, to assess the extent of staining
by this antibody and to see whether, there was any
relationship with tumour grade or type prior to undertaking
a longer term follow-up of these patients.
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Materials and methods
Cervical biopsies
Biopsies from 25 squamous carcinomas and 6 adeno-
carcinomas were obtained from the same number of patients
(one biopsy from each) with known invasive carcinoma of
the cervix prior to radiotherapy. All of the tissue was snap
frozen and stored in liquid nitrogen. H&E sections of the
original diagnostic biopsy material (formalin fixed and
paraffin-embedded) were obtained from the files of the John
Radcliffe Histopathology Department or requested from the
patient's referring hospital.
Immunocytochemistry
Cryostat sections were stained with the monoclonal antibody
Ki67 (DAKO-PC) using the APAAP immunoalkaline phos-
phatase technique (Cordell et al., 1984). Routinely processed
material (formalin fixed, paraffin-embedded) is unsuitable for
staining with Ki67 since the antigen recognised by this
antibody is destroyed by conventional fixation.
Proliferation assessment
The total number of cells and the number of positively
labelled cells in a given area (2mm2) were counted using a
graticule. Five different randomly selected areas of the
cryostat section were assessed and the number of positive
cells expressed as a percentage of the total number of cells
(>500) counted. This provided an easy and reproducible
method of assessing the extent of Ki67 staining.
The number of mitotic figures per high power field was
obtained by counting and averaging values from 10 fields in
H & E sections of the original diagnostic biopsy.
Assessment of tumour grade and type
The grade of the tumour was assigned by degree of
differentiation. Grade I tumours include those showing
relatively orderly maturation of cells, keratinization, minor
pleomorphism and few mitoses (Goellner, 1976). The grade
was increased as the degree of disorderliness and pleo-
morphism, lack of keratinization, and number of mitoses
increased. Classification by cell type was performed
according to the criteria used by Reagan et al. (1957). They
separated cervical squamous cell carcinomas into three
groups; large cell nonkeratinizing, large cell keratinizing, and
small cell carcinomas. In addition, in this study, adeno-
carcinomas were included as a separate group.
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Results
The histogram in Figure plots the number of cases against
the percentage of cells (which divided conveniently into 4
groups) labelled with the monoclonal antibody Ki67 for 21
squamous cell carcinomas and 6 adenocarcinomas of the
cervix uteri. The 4 remaining cases of squamous cell
carcinoma were eliminated from this study due to cyto-
plasmic labelling which made accurate estimation of nuclear
staining impossible. Between individual cases the percentage
of labelled nuclei showed wide variation over a range of 10-
50% (Figure 1). There was also a smaller variation (± 10%)
amongst different areas within an individual biopsy. The
counting and averaging of results from 5 randomly chosen
fields gave consistently reproducible results thus overcoming
the problem of intra-biopsy variation in Ki67 staining.
Examples of the immunohistological staining patterns using
Ki67 are illustrated in Figure 2. It was noticeable that the
number of labelled nuclei was highest around the periphery
of tumour islands particularly when the central area showed
evidence of differentiation (Figure 2c). There was no signifi-
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Figure 1 Histogram illustrating the number of cases of cervical
cancer within each of the four categories of Ki67 labelling.
Figure 2 This figure illustrates the different staining patterns
with Ki67 seen in cryostat sections of cervical carcinoma
biopsies. (a) is a tumour with a low growth fraction (18% of
cells labelled). APAAP x 250; (b) is a tumour with a high
growth fraction (40% of cells labelled). APAAP x 400; (c)
demonstrates the peripheral localization of proliferating nuclei
seen in well differentiated squamous areas. APAAP x 250.
Labelled nuclei are indicated by arrows in each case.
cant relationship between the percentage of positive cells and
tumour grade (Table I) or cell type. In Figure 3 the number
of mitotic figures per high power field is plotted against the
number of Ki67 labelled nuclei revealing only a weak
correlation (r=0.46).
Table I Relationship between the mean per-
centage values of Ki67 staining and tumour
differentiation in cervical biopsies
No. Ki67 %
Tumour gradea cases (mean)
I 1 33
II 13 30
III 10 31
IV 3 32
aTumours (21 squamous cell carcinomas and
6 adenocarcinomas) graded according to the
criteria of Goellner (1976).
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Figure 3 Scatter plot of mitotic index against percentage of cells
labelled by Ki67. The simple curve fit line shows there is little
correlation between these two parameters.
Discussion
There have been many attempts to use histological criteria to
predict the clinical behaviour of carcinoma of the cervix,
mostly with little or no success. Goellner (1976) evaluated
196 cases of invasive squamous carcinoma of the cervix and
found no significant relationship between prognosis and
grade or histological type of tumours within any stage.
Crissman et al. (1985) evaluated multiple histopathological
parameters of 70 squamous cell carcinomas of the cervix,
including cell size, inflammatory response and degree of
keratinization but failed to demonstrate any significant
prognostic indicator. The number of mitoses per high power
field has also been considered as a possible prognostic
indicator but found to be of no value (Crissman et al., 1985).
These findings are in agreement with the results presented
here, in which there appeared to be little or no correlation
between the tumour growth rate as measured by Ki67 and
the tumour grade, type or mitotic index. This differs from
the findings of Barnard et al. (1987) who report a positive
correlation between Ki67 labelling and the mitotic index for
breast carcinoma. Whether this reflects genuine differences
between these tumours or a divergence in the manner in
which each study has assessed this parameter will require
further study with longer clinical follow up.
There are reports which suggest that the small cell type of
cervical carcinoma (Ng & Atkin, 1973; van Nagell et al.,
1977) has a worse prognosis than the large cell non-
keratinizing and keratinizing squamous cell variants of
cervical carcinoma. However these tumours are relatively
uncommon and thus account for only a small percentage of
carcinoma of the cervix.
Immunohistochemistry has as yet been of limited value as
a tool for predicting behaviour of cervical dysplasia and
neoplasia. Bobrow et al. (1986) have suggested that a change
in cytokeratin expression by neoplastic cervical epithelium
(CIN) as reflected by different degrees of staining with the
anti-cytokeratin antibody CAM 5.2, may be a marker of
invasive potential. This conclusion has not however been
confirmed by a similar study conducted by Wells et al.
(1986). Fray et al. (1984) studied tumour associated antigens
detected by four different monoclonal antibodies (HMFG-1
and 2, Cal and anti-CEA) but found their prognostic
significance to be limited.
There is evidence to suggest that tumour proliferation
rates are related to clinical behaviour (Straus et al., 1983).
As early as 1966 Breur showed that with increasing tumour
doubling time the length of survival from presentation to
death progressively increased. More recent studies using
tritiated thymidine labelling index as a kinetic parameter in
patients with breast carcinoma support these findings by
showing that a low labelling index is associated with a better
prognosis (Meyer et al., 1978; Straus & Moran, 1980).
However most of the techniques used in the past decade or
so to measure tumour proliferation rate are cumbersome and
time consuming and hence have not found a place in clinical
practice. A simple and reliable guide to tumour proliferation
has therefore been sought for routine use.
In the present study the monoclonal antibody Ki67 has
been shown to give a simple and reliable guide to the size of
the growth fraction in the majority of cervical tumour
biopsies examined. Only 4 out of 25 cases of squamous cell
carcinoma could not be assessed due to cytoplasmic staining
by Ki67 and were therefore eliminated from the study. The
reason for this cross-reaction is unclear although it has been
noted in a number of cases of both benign and malignant
squamous epithelium by ourselves and others (Gerdes and
Stein, personal communication). Recently a technique for
staining nucleolar organizer regions in tissue sections has
been described as a possible method for assessing prognosis
in tumours such as lymphoma (Crocker & Nar, 1987) and
melanocytic lesions (Crocker & Skilbeck, 1987). This
technique has not as yet been applied to cervical pathology
although it would obviously be valuable to compare future
results with those achieved using monoclonal antibody Ki67.
Ki67, the monoclonal antibody used in the present study,
identifies an as yet uncharacterized antigen which has been
shown to be present in cell nuclei in all stages of the cell cycle
except the Go phase (Gerdes et al., 1984a) and therefore
gives a convenient guide to tumour growth fraction. Indeed,
as with other tumour kinetic studies, Ki67 labelling has been
shown to correlate with tumour behaviour in recent
preliminary studies. For breast tumours Gerdes et al. (1986)
found that benign lesions had a mean value of 3% Ki67
positive cells compared to 16.6% for mammary carcinomas.
Hall et al. (1987) have studied 141 biopsies (from 138
patients) of non-Hodgkin's lymphoma and consider that
Ki67 immunostaining may be clinically useful particularly in
relation to prediction of lymphoma behaviour in low grade
non-Hodgkin's lymphomas.
The present study has shown that biopsies of cervical
carcinoma display a wide range (10-50%) of tumour cell
nuclei which are labelled by monoclonal antibody Ki67
which presumably reflects considerable variation in the
growth fraction of these tumours. In addition the
distribution of nuclear labelling and hence proliferative
activity varied within individual cases with central areas
showing cell maturation and keratinization displaying little
or no staining compared with the more actively proliferating
peripheral portions. A similar pattern of proliferation has
been reported in well differentiated carcinomas of the
rectum, foot and oral cavity, using autoradiographic
techniques (Prioleau et al., 1980).
The most important question raised by this study, as in
the case of other tumour types, e.g. lung (Gatter et al., 1986)
and breast (Gerdes et al., 1986) studied with monoclonal
antibody Ki67 is whether or not the variation in nuclear
labelling with Ki67 (and hence this method of measuring
growth fraction) correlates with clinical behaviour. Long
term clinicopathological studies are underway to answer
these questions. They will, however, require independent
confirmation and since retrospective studies are not possible
with Ki67, or any of the other conventional means of
assessing tumour growth fraction, it is to be hoped that
others will undertake similar prospective trials. This study
has restricted itself to biopsy material of invasive cervical
carcinomas because of its availability as fresh specimens.
Now that it has been shown that this material is suitable for
assessment by monoclonal antibody Ki67 it should be
possible to extend this approach to cervical intra-epithelial
neoplasia (CIN) in the form of both tissue biopsies and
cytological specimens.
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